212 related articles for article (PubMed ID: 19830497)
1. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Chiou JF; Tai CJ; Huang MT; Wei PL; Wang YH; An J; Wu CH; Liu TZ; Chang YJ
Ann Surg Oncol; 2010 Feb; 17(2):603-12. PubMed ID: 19830497
[TBL] [Abstract][Full Text] [Related]
2. Glucose-regulated protein 78 (GRP78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma.
Chang YJ; Tai CJ; Kuo LJ; Wei PL; Liang HH; Liu TZ; Wang W; Tai CJ; Ho YS; Wu CH; Huang MT
Ann Surg Oncol; 2011 Aug; 18(8):2395-403. PubMed ID: 21347788
[TBL] [Abstract][Full Text] [Related]
3. Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carcinoma.
Tung JN; Cheng YW; Hsu CH; Liu TZ; Hsieh PY; Ting LL; Ko HL; Chang YJ; Chiou JF; Wu AT
Ann Surg Oncol; 2011 May; 18(5):1492-500. PubMed ID: 21181559
[TBL] [Abstract][Full Text] [Related]
4. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
6. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
8. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Galmiche A; Ezzoukhry Z; François C; Louandre C; Sabbagh C; Nguyen-Khac E; Descamps V; Trouillet N; Godin C; Regimbeau JM; Joly JP; Barbare JC; Duverlie G; Mazière JC; Chatelain D
Mol Cancer Res; 2010 Aug; 8(8):1116-25. PubMed ID: 20647330
[TBL] [Abstract][Full Text] [Related]
9. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL
Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624
[TBL] [Abstract][Full Text] [Related]
13. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
14. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells.
Tai CJ; Chin-Sheng H; Kuo LJ; Wei PL; Lu HH; Chen HA; Liu TZ; Liu JJ; Liu DZ; Ho YS; Wu CH; Chang YJ
Ann Surg Oncol; 2012 Jan; 19(1):336-43. PubMed ID: 21516372
[TBL] [Abstract][Full Text] [Related]
15. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
[TBL] [Abstract][Full Text] [Related]
16. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma.
Chang YJ; Chiu CC; Wu CH; An J; Wu CC; Liu TZ; Wei PL; Huang MT
Ann Surg Oncol; 2010 Jun; 17(6):1703-9. PubMed ID: 20087778
[TBL] [Abstract][Full Text] [Related]
17. [The influence of downregulation of ezrin expression by RNA interference on the growth and metastasis of hepatocellular carcinoma: experiment in vitro].
Zhang Y; Hu MY; Chen BH; Wang ZJ; Zha XL; Liu KD
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):530-5. PubMed ID: 16681881
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Li XF; Gong RY; Wang M; Yan ZL; Yuan B; Wang K; Shi LH
Biochem Biophys Res Commun; 2012 Feb; 418(3):531-6. PubMed ID: 22285185
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway.
Zhang W; Wu J; Zhou L; Xie HY; Zheng SS
Indian J Exp Biol; 2010 Dec; 48(12):1167-74. PubMed ID: 21250597
[TBL] [Abstract][Full Text] [Related]
20. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
